Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Pharmaceutical company focused on restoring sexual function reports Q1 results
May 26th, 2005
Vivus, Inc. (VVUS), a specialty pharmaceutical company focused on the research, development and commercialization of products to restore sexual function in women and men, announced its accomplishments and financial results for the 3 months ended March 31, 2005. The quarter ended March 31, 2005 was marked by several achievements including completion of avanafil phase 2 patient enrollment. Avanafil is an investigational drug being studied for the treatment of erectile dysfunction. It is a highly selective, orally administered phosphodiesterase type 5 (PDE5) inhibitor. This multi-center, double-blind, randomized, placebo-controlled, parallel-design...
Source: Women's Health Weekly (2005-05-26)
|
